Bicara's Cancer Trials And Launch Preparations Push Quarterly Loss To $71.2 Million

The experimental cancer-drug developer expects its $442.3 million in cash and investments to cover operations into the first half of 2029.

Share
Bicara's Cancer Trials And Launch Preparations Push Quarterly Loss To $71.2 Million

Bicara Therapeutics, which is testing ficerafusp alfa for HPV-negative head and neck cancer, posted a third-quarter loss of $71.2 million, compared with $36.3 million a year earlier, in results accompanying Monday's SEC filing. Clinical trials, hiring and preparations for a potential commercial launch drove higher spending.

Trials And Hiring Expand The Bill

Research spending totaled $56.5 million in the third quarter, against $33.0 million in the corresponding 2025 period. Bicara attributed the increase primarily to its pivotal head and neck cancer trial, its alternate-dosing trial, early-stage expansion studies and personnel costs.

Administrative costs reached $19.2 million, compared with $7.7 million a year earlier. Additional staff and professional fees accounted for most of that increase as Bicara expanded its organization and prepared for potential commercialization.

The loss per share widened to $1.04 from $0.67. For the first nine months of 2026, Bicara lost $182.9 million, compared with $100.6 million in the same period of 2025. Quarterly expenses included $10.0 million in non-cash stock-based pay, versus $3.6 million a year earlier.

Bicara ended September with $442.3 million in cash and investments, compared with $414.8 million at year-end 2025. Management expects that money to support operations into the first half of 2029 under its current operating and development plans.

A Cancer Drug With Dosing Options

Ficerafusp alfa combines a cancer-cell-targeting antibody with a component designed to block signals involved in tumor growth and immune suppression. Bicara remains a clinical-stage developer: its medicines are being studied in patients rather than sold commercially.

Bicara described enrollment as substantial in its pivotal study of initial treatment for recurrent or metastatic HPV-negative head and neck cancer. The global mid-to-late-stage trial tests ficerafusp alfa alongside pembrolizumab; management expects interim results in mid-2027.

A separate randomized, open-label study is testing whether patients can receive treatment less often. Both groups receive pembrolizumab: one receives 1,500 milligrams of ficerafusp alfa weekly, while the other receives that weekly dose for 12 weeks, then 2,250 milligrams every three weeks. Bicara expects those results to be available by the time of potential U.S. approval.

Ryan Cohlhepp, Bicara's president, interim chief executive officer and chief operating officer, said the company is focused on “moving with speed and aiming for ficerafusp alfa to enter the market with a competitive profile.” He said its commercial leadership team is now in place.

Expansion Beyond The Pivotal Trial

The organizational expansion includes office space. On August 21, 2026, Bicara signed a sublease with Wayfair for approximately 35,090 square feet at 10 St. James Avenue in Boston for its new corporate headquarters.

Bicara also plans to present laboratory research on ficerafusp alfa's effects on fibrosis and drug penetration at the European Society for Medical Oncology Immuno-Oncology & Advanced Therapies Congress in London, December 14–16.

In January 2027, it plans to present early-stage colorectal cancer data testing the drug alone and with pembrolizumab. That expansion study covers patients with metastatic disease receiving third-line or later treatment, whose tumors have no RAS or BRAF mutations and are microsatellite stable.

The pivotal head and neck cancer trial's planned mid-2027 interim results remain the next major clinical readout on Bicara's stated development schedule.

Sources